Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 11, Issue 1, 1998, Pages 55-63

  Borgström, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Inhalers; L:T ratio; Lung deposition

Indexed keywords

BUDESONIDE; SALBUTAMOL; TERBUTALINE;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; POWDER INHALER;

EID: 0031906450     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.1998.11.55     Document Type: Article

References (35)

1. Borgström, L., E. Derom, E. Ståhl, E. Wåhlin-Boll, and R. Pauwels. 1996. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am. J. Respir, Crit. Care Med. 153:1636-1640.
2. Löfdahl, C.G., L. Andersson, E. Bondesson, L.G. Carlsson, K. Friberg, Y. Hörnblad, P. Jemsby, J. Rosenborg, S. Werner, and N. Svedmyr. 1994. Salbutamol doses inhaled via Turbohaler® gives a better bronchodilating effect than when given via a pressurized metered dose inhaler. Eur. Respir. J. 7(Suppl):49.
3. Lofdahl, C.G., L. Andersson, L.G. Carlsson, K. Friberg, Y. Hornblad, P. Jemsby, S. Werner, and N. Svedmyr. 1994. Lower nominal dose required of inhaled salbutamol via Turbohaler® compared with pressurized metered dose inhaler, for the same bronchodilating effect [abstract]. Am. J. Respir Crit. Care Med. 149:A219.
4. Olsson, B., L. Borgström, L. Asking, and E. Bondesson. 1996. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In R. Dalby, P. Byron, and S. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, Illinois, 273-281.
5. Borgström, L. 1992. A possible new approach of comparing different inhalers and inhaled substances. J. Aerosol Med. 5:298.
6. Briant, R., E. Blackwell, F. Williams, D. Davies, and C. Dollery. 1973. The metabolism of sympathomimetic bronchodilator drugs by the isolated perfused dog lung. Xenobiotica 3:787-799.
7. Andersson, P. and Å. Ryrfeldt. 1984. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17a, 21-dipropionate in human liver and lung homogenate. J. Pharm. Pharmacol. 36:763-765.
8. Lipworth, B., R. Clark, D. Dhillon, T. Moreland, A. Struthers, and D. McDevitt. 1989. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur. J. Clin. Pharmacol. 37:567-571.
9. Morgan, D., J. Paull, B. Richmond, E. Wilson-Evered, and S. Ziccone. 1986. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol. 22:587-593.
10. Thorsson, L., S. Edsbäcker, and T.-B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 7:1839-1844.
11. Dahlström, K., S. Edsbäcker, and A. Källén. 1996. Rectal pharmacokinetics of budesonide. Eur. J. Clin. Pharmacol. 49:293-298.
12. Nyberg, L. 1984. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur. J. Respir. Dis. 65:149-160.
13. Newman, S., A. Weisz, N. Talaee, and S. Clarke. 1991. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhalation technique. Thorax 46:712-716.
14. Melchor, R., M. Biddiscombe, V. Mak, M. Short, and S. Spiro. 1993. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.
15. Biddiscombe, M., R. Melchor, V. Mak, R. Marriott, A. Taylor, M. Short, and S. Spiro. 1993. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised metered dose and dry powder inhalers. Int. J. Pharmacol. 91:111-121.
16. Newman, S. and S. Clarke. 1993. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest 103:1442-1446.
17. 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and from a novel multiple-dose inhaler. S.T.P. Pharm Sci. 4:29-32.
18. Borgström, L., L. Asking, O. Beckman, E. Bondesson, A. Källén, and B. Olsson. 1996. Dose variation, within and between individuals, with different inhalation systems. In N. Dalby, P. Byron, and S. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, Illinois, 19-24.
19. 99mTc-labelled salbutamol from a novel multiple dose powder inhaler in healthy volunteers and in asthmatics. J. Aerosol Med. 6:72.
20. Borgström, L., E. Bondesson, F. Morén, E. Trofast, and S. Newman. 1994. Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7:69-73.
21. Borgström, L. and M. Nilsson. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline. Pharm. Res. 7:1068-1070.
22. Borgström, L. and S. Newman. 1993. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or Turbuhaler. Int. J. Pharmacol. 97:47-53.
23. Newman, S., K. Steed, G. Hooper, A. Källén, and L. Borgström. 1995. Comparison of gamma scintigraphy and pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm. Res. 12:231-236.
24. Newman, S., F. Morén, E. Trofast, N. Talaee, and S. Clarke. 1991. Terbutaline sulphate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharmacol. 74:209-213.
25. Borgström, L., S. Newman, A. Weisz, and F. Morén. 1992. Pulmonary deposition of inhaled terbutaline: Comparison of scanning gamma camera and urinary excretion methods. J. Pharm. Sci. 81:753-755.
26. Harding, S. 1990. The human pharmacology of fluticasone propionate. Respir. Med. 84:25-29.
27. Barry, P. and C. O'Callaghan. 1994. Poor output of salbutamol from a spacer device-the effect of spacer static charge and multiple actuations. Thorax 49:402P.
28. Barry, P. and C. O'Callaghan. 1994. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur. Respir. J. 7:1707-1709.
29. Berg, E. 1995. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J. Aerosol Med. 8(suppl):3-11.
30. Bisgaard, H. 1996. Drug delivery from inhaler devices: Lung deposition, clinical effect, and cost-effectiveness vary. B.M.J. 313:895-896.
31. Sinninghe Damsté, M.E.J. 1991. Turbuhaler, a clinical overview. J. Aerosol Med. 4(suppl. 1):53.
32. Corris, P., C. Hardy, A. Richardson, M. Taylor, and P. Richardson. 1992. The efficacy and acceptability of two breath-actuated, multi-dose, dry-powder inhalers in the treatment of chronic asthma. Br. J. Clin. Res. 3:139-150.
33. Schlaepp, M., K. Edwards, and R. Fuller. 1996. Patient perception of the Diskus inhaler: A comparison with the Turbuhaler inhaler. Br. J. Clin. Pract. 50:14-19.
34. Jackson, L., E. Ståhl, and S. Holgate. 1994. Terbutaline via pressurised metered dose inhaled (P-MDI) and Turbuhaler in highly reactive asthmatic patients. Eur. Respir. J. 7:1598-1601.
35. Selroos, O., A.-B. Löfroos, A. Pietinalho, and H. Riska. 1994. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 49:1228-1230.